XML 26 R13.htm IDEA: XBRL DOCUMENT v3.24.3
Segment Information
 9 Months Ended
Sep. 27, 2024
Segment Reporting [Abstract]  
Segment Information SEGMENT INFORMATION
The Company operates and reports its results in business segments consisting of the Biotechnology, Life Sciences and Diagnostics segments. Operating profit represents total revenues less operating expenses, excluding nonoperating income and expense, interest and income taxes. Operating profit amounts in the Other segment consist of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance. Intersegment amounts are not significant and are eliminated to arrive at consolidated totals.
Segment results are shown below ($ in millions):
 Three-Month Period EndedNine-Month Period Ended
September 27, 2024September 29, 2023September 27, 2024September 29, 2023
Sales:
Biotechnology$1,653 $1,664 $4,890 $5,413 
Life Sciences1,782 1,706 5,297 5,211 
Diagnostics2,363 2,254 7,150 6,861 
Total$5,798 $5,624 $17,337 $17,485 
Operating profit:
Biotechnology$390 $417 $1,177 $1,493 
Life Sciences35 313 503 974 
Diagnostics615 539 2,001 1,640 
Other(82)(84)(243)(242)
Total$958 $1,185 $3,438 $3,865